| 消渴丸治疗2型糖尿病合并代谢综合征的临床研究 |
| Clinical study of Xiaoke Pill in treatment of type 2 diabetes mellitus complicated with metabolic syndrome |
| DOI： |
| 中文关键词: 2型糖尿病 代谢综合征 消渴丸 达格列净 |
| 英文关键词: Type 2 diabetes mellitus Metabolic syndrome Xiaoke pill dapagliflozin |
| 基金项目: |
|
| 摘要点击次数: |
| 全文下载次数: |
| 中文摘要: |
| 目的：探索消渴丸联合达格列净治疗2型糖尿病合并代谢综合征的有效性和安全性。
方法：纳入邵武市立医院的60例2型糖尿病合并代谢综合征患者，随机分为消渴丸组和对照组。对照组口服达格列净，消渴丸组在对照组的基础上加服消渴丸，疗程12周。观察两组治疗前后血糖（空腹血糖、餐后两小时血糖、糖化血红蛋白）、血脂（总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、甘油三酯）和血压的变化差异。观察研究期间两组不良反应发生情况。
结果：治疗4、8、12周后，与对照组相比，消渴丸组显著降低FPG水平（P值均＜0.05）。治疗前后两组2hPG、HbAlc差异均无统计学意义（P值均＞0.05）。治疗8、12周后，与对照组相比，消渴丸显著降低TC水平，差异有统计学意义（均P＜0.05）。治疗前后两组TG、HDL-C、LDL-C差异无统计学意义（P值均＞0.05）。治疗12周后，消渴丸组收缩压显著低于对照组（P＜0.05）。治疗前后两组收缩压差异无统计学意义（均P＞0.05）。两组患者均未出现不良反应。
结论：消渴丸联合达格列净治疗2型糖尿病合并代谢综合征安全有效。 |
| 英文摘要: |
| Objective: To explore the efficacy and safety of Xiaoke Pill combined with dapagliflozin in the treatment of type 2 diabetes mellituswith metabolic syndrome.
Method: Sixty patients with type 2 diabetes mellitus complicated with metabolic syndrome in Shaowu Municiple Hospital of Fujian Province were randomly divided into Xiaoke pill group and control group. The control group was given dapagliflozin orally. The Xiaoke pill group was given Xiaoke pill on the basis of the control group. The course of treatment was 12 weeks. The main outcome measures included fasting blood glucose (FPG), two-hour postmeal blood glucose (2h PG), glycated hemoglobin (HbA1c), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG), and blood pressure. Adverse reactions were observed during the study.
Result: Compared to the control group，the treatment of Xiaoke Pill significantly decreased the level of FPG on 4, 8 and 12 weeks (all P < 0.05). There was no significant difference between the two groups in 2hPG and HbAlc (all P > 0.05). Compared to the control group，the intervention of Xiaoke Pill significantly reduced the level of TC on 8 and 12 weeks (all P < 0.05). There was no significant difference between the two groups in TG, HDL-C and LDL-C (all P > 0.05). The systolic blood pressure in Xiaoke pill group was significantly lower than that in control group with treatment of 12 weeks (P < 0.05). There was no significant difference in systolic blood pressure between the two groups (all P > 0.05). No adverse reactions were reported in both groups.
Conclusion: Xiaoke Pill combined with Daglipzin treated type 2 diabetes mellitus with metabolic syndrome with good efficacy and safety. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |